Agilent Technologies, Inc. (0HAV.L)
| Previous close | 137.91 |
| Open | 139.55 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 138.88 - 141.75 |
| 52-week range | 96.99 - 151.48 |
| Volume | |
| Avg. volume | 3,613 |
| Market cap | 444.709M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 0.34 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29
SANTA CLARA, Calif., May 02, 2024--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT.
- Business Wire
Padraig McDonnell Assumes Agilent CEO Role
SANTA CLARA, Calif., May 01, 2024--Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.
- Business Wire
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution
SANTA CLARA, Calif., May 01, 2024--Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development.
